ProFunds Biotechnology UltraSector Fund Service Class (BIPSX) is a leveraged mutual fund that seeks daily investment results, before fees and expenses, corresponding to two times (2x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund provides amplified exposure to the biotechnology sector through derivative instruments, including swap agreements, futures contracts, and options; it invests substantially all assets in financial instruments that replicate the index's movements rather than holding individual biotechnology stocks directly. ProFunds Group LLC, founded in 1997 and headquartered in Bethesda, Maryland, USA, serves as the investment adviser, offering a range of leveraged and inverse sector funds targeting institutional and retail investors focused on short-term trading strategies in U.S. equities. The fund operates primarily in the U.S. market, with no significant international geographic footprint beyond standard global derivative counterparties. In recent developments, ProFunds announced enhancements to its UltraSector fund lineup in 2024, including improved liquidity provisions and expanded swap counterparty arrangements to mitigate leverage decay risks amid volatile biotech market conditions; no major acquisitions, funding rounds, or name changes have occurred within the last two years.